Selenocystine-induced cell apoptosis and S-phase arrest inhibit human triple-negative breast cancer cell proliferation

详细信息    查看全文

• 作者：Meijun Long ; Juekun Wu ; Junwen Hao ; Wei Liu…
• 关键词：Selenocystine ; Apoptosis ; S ; phase arrest ; Triple ; negative breast cancer ; Proliferation
• 刊名：In Vitro Cellular & Developmental Biology - Animal
• 出版年：2015
• 出版时间：November 2015
• 年：2015
• 卷：51
• 期：10
• 页码：1077-1084
• 全文大小：5,249 KB
• 参考文献：Alfarouk KO, Muddathir AK, Shayoub ME (2011) Tumor acidity as evolutionary spite. Cancers (Basel) 3:408鈥?4CrossRef
  Amaral AF, Cantor KP, Silverman DT, Malats N (2010) Selenium and bladder cancer risk: a meta-analysis. Cancer Epidemiol Biomarkers Prev 19:2407鈥?5CrossRef PubMed
  Babaknejad N, Sayehmiri F, Sayehmiri K, Rahimifar P, Bahrami S, Delpesheh A, Hemati F, Alizadeh S (2014) The relationship between selenium levels and breast cancer: a systematic review and meta-analysis. Biol Trace Elem Res 159:1鈥?CrossRef PubMed
  Bosch A, Eroles P, Zaragoza R, Vina JR, Lluch A (2010) Triple-negative breast cancer: molecular features, pathogenesis, treatment and current lines of research. Cancer Treat Rev 36:206鈥?5CrossRef PubMed
  Cairns RA, Harris IS, Mak TW (2011) Regulation of cancer cell metabolism. Nat Rev Cancer 11:85鈥?5CrossRef PubMed
  Carey LA, Dees EC, Sawyer L, Gatti L, Moore DT, Collichio F, Ollila DW, Sartor CI, Graham ML, Perou CM (2007) The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 13:2329鈥?4CrossRef PubMed
  Chen T, Wong YS (2008a) Selenocystine induces apoptosis of A375 human melanoma cells by activating ROS-mediated mitochondrial pathway and p53 phosphorylation. Cell Mol Life Sci 65:2763鈥?5CrossRef PubMed
  Chen T, Wong YS (2008b) Selenocystine induces S-phase arrest and apoptosis in human breast adenocarcinoma MCF-7 cells by modulating ERK and Akt phosphorylation. J Agric Food Chem 56:10574鈥?1CrossRef PubMed
  Chen T, Wong YS (2009a) Selenocystine induces reactive oxygen species-mediated apoptosis in human cancer cells. Biomed Pharmacother 63:105鈥?3CrossRef PubMed
  Chen T, Wong YS (2009b) Selenocystine induces caspase-independent apoptosis in MCF-7 human breast carcinoma cells with involvement of p53 phosphorylation and reactive oxygen species generation. Int J Biochem Cell Biol 41:666鈥?6CrossRef PubMed
  Cleator S, Heller W, Coombes RC (2007) Triple-negative breast cancer: therapeutic options. Lancet Oncol 8:235鈥?4CrossRef PubMed
  Diplock AT (1987) Trace elements in human health with special reference to selenium. Am J Clin Nutr 45:1313鈥?2PubMed
  Elias AD (2010) Triple-negative breast cancer: a short review. Am J Clin Oncol 33:637鈥?5CrossRef PubMed
  Fernandes A P, Gandin V (2014) Selenium compounds as therapeutic agents in cancer. Biochim Biophys Acta
  Foulkes WD, Smith IE, Reis-Filho JS (2010) Triple-negative breast cancer. N Engl J Med 363:1938鈥?8CrossRef PubMed
  Fritz H, Kennedy D, Fergusson D, Fernandes R, Cooley K, Seely A, Sagar S, Wong R, Seely D (2011) Selenium and lung cancer: a systematic review and meta analysis. PLoS One 6, e26259PubMedCentral CrossRef PubMed
  Gatenby RA, Gillies RJ (2004) Why do cancers have high aerobic glycolysis? Nat Rev Cancer 4:891鈥?CrossRef PubMed
  Goel A, Fuerst F, Hotchkiss E, Boland CR (2006) Selenomethionine induces p53 mediated cell cycle arrest and apoptosis in human colon cancer cells. Cancer Biol Ther 5(5):529鈥?35
  Haffty BG, Yang Q, Reiss M, Kearney T, Higgins SA, Weidhaas J, Harris L, Hait W, Toppmeyer D (2006) Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J Clin Oncol 24:5652鈥?CrossRef PubMed
  Hurst R, Hooper L, Norat T, Lau R, Aune D, Greenwood DC, Vieira R, Collings R, Harvey LJ, Sterne JA, Beynon R, Savovic J, Fairweather-Tait SJ (2012) Selenium and prostate cancer: systematic review and meta-analysis. Am J Clin Nutr 96:111鈥?2CrossRef PubMed
  Jiang C, Wang Z, Gunther H, L眉 J (2002) Distinct effects of methylseleninic acid versus selenite on apoptosis, cell cycle, and protein kinase pathways in DU145 human prostate cancer cells. Mol Cancer Ther 1(12):1059鈥?066
  Kalimuthu S, Se-Kwon K (2013) Cell survival and apoptosis signaling as therapeutic target for cancer: marine bioactive compounds. Int J Mol Sci 14(2):2334鈥?354
  Kim JW, Dang CV (2006) Cancer's molecular sweet tooth and the Warburg effect. Cancer Res 66:8927鈥?0CrossRef PubMed
  Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, Pietenpol JA (2011) Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 121:2750鈥?7PubMedCentral CrossRef PubMed
  Liedtke C, Mazouni C, Hess KR, Andre F, Tordai A, Mejia JA, Symmans WF, Gonzalez-Angulo AM, Hennessy B, Green M, Cristofanilli M, Hortobagyi GN, Pusztai L (2008) Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 26:1275鈥?1CrossRef PubMed
  Pais R, Dumitrascu DL (2013) Do antioxidants prevent colorectal cancer? A meta-analysis. Rom J Intern Med 51:152鈥?3PubMed
  Poerschke RL, Moos PJ (2011) Thioredoxin reductase 1 knockdown enhances selenazolidine cytotoxicity in human lung cancer cells via mitochondrial dysfunction. Biochem Pharmacol 81:211鈥?1PubMedCentral CrossRef PubMed
  Rakha EA, Ellis IO (2009) Triple-negative/basal-like breast cancer: review. Pathology 41:40鈥?CrossRef PubMed
  Rakha EA, El-Sayed ME, Green AR, Lee AH, Robertson JF, Ellis IO (2007) Prognostic markers in triple-negative breast cancer. Cancer 109:25鈥?2CrossRef PubMed
  Rayman MP (2000) The importance of selenium to human health. Lancet 356:233鈥?1CrossRef PubMed
  Rayman MP (2012) Selenium and human health. Lancet 379:1256鈥?8CrossRef PubMed
  Roman M, Jitaru P, Barbante C (2014) Selenium biochemistry and its role for human health. Metallomics 6:25鈥?4CrossRef PubMed
  Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CJ, Davidson NE, Tan-Chiu E, Martino S, Paik S, Kaufman PA, Swain SM, Pisansky TM, Fehrenbacher L, Kutteh LA, Vogel VG, Visscher DW, Yothers G, Jenkins RB, Brown AM, Dakhil SR, Mamounas EP, Lingle WL, Klein PM, Ingle JN, Wolmark N (2005) Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353:1673鈥?4CrossRef PubMed
  Rouzier R, Perou CM, Symmans WF, Ibrahim N, Cristofanilli M, Anderson K, Hess KR, Stec J, Ayers M, Wagner P, Morandi P, Fan C, Rabiul I, Ross JS, Hortobagyi GN, Pusztai L (2005) Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 11:5678鈥?5CrossRef PubMed
  Shen F, W S Cai, J L Li, Z Feng, J Cao & B Xu (2015) The Association Between Serum Levels of Selenium, Copper, and Magnesium with Thyroid Cancer: a Meta-analysis. Biol Trace Elem Res
  Silver DP, Richardson AL, Eklund AC, Wang ZC, Szallasi Z, Li Q, Juul N, Leong CO, Calogrias D, Buraimoh A, Fatima A, Gelman RS, Ryan PD, Tung NM, De Nicolo A, Ganesan S, Miron A, Colin C, Sgroi DC, Ellisen LW, Winer EP, Garber JE (2010) Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer. J Clin Oncol 28:1145鈥?3PubMedCentral CrossRef PubMed
  Singh RP, Dhanalakshmi S, Agarwal R (2002) Phytochemicals as cell cycle modulators--a less toxic approach in halting human cancers. Cell Cycle 1(3):156鈥?61
  Toogood PL (2002) Progress toward the development of agents to modulate the cell cycle. Curr Opin Chem Biol 6(4):472鈥?78
  Troester MA, Hoadley KA, Sorlie T, Herbert BS, Borresen-Dale AL, Lonning PE, Shay JW, Kaufmann WK, Perou CM (2004) Cell-type-specific responses to chemotherapeutics in breast cancer. Cancer Res 64:4218鈥?6CrossRef PubMed
  Unni E, Koul D, Yung WK, Sinha R (2005) Se-methylselenocysteine inhibits phosphatidylinositol 3-kinase activity of mouse mammary epithelial tumor cells in vitro. Breast Cancer Res 7(5):R699鈥揜707
  Venkateswaran V, Klotz LH, Fleshner NE (2002) Selenium modulation of cell proliferation and cell cycle biomarkers in human prostate carcinoma cell lines. Cancer Res 62(9):2540鈥?545
  Wallenberg M, Misra S, Wasik AM, Marzano C, Bjornstedt M, Gandin V, Fernandes AP (2014) Selenium induces a multi-targeted cell death process in addition to ROS formation. J Cell Mol Med 18:671鈥?4PubMedCentral CrossRef PubMed
  Wang Z, Hu H, Li G, Lee HJ, Jiang C, Kim SH, L眉 J (2008) Methylseleninic acid inhibits microvascular endothelial G1 cell cycle progression and decreases tumor microvessel density. Int J Cancer 122(1):15鈥?4
  Wei WQ, Abnet CC, Qiao YL, Dawsey SM, Dong ZW, Sun XD, Fan JH, Gunter EW, Taylor PR, Mark SD (2004) Prospective study of serum selenium concentrations and esophageal and gastric cardia cancer, heart disease, stroke, and total death. Am J Clin Nutr 79:80鈥?PubMed
  Zhong W, Oberley TD (2001) Redox-mediated effects of selenium on apoptosis and cell cycle in the LNCaP human prostate cancer cell line. Cancer Res 61(19):7071鈥?078
  
• 作者单位：Meijun Long (1)
  Juekun Wu (1)
  Junwen Hao (1) (2)
  Wei Liu (1) (3)
  Yong Tang (1) (4)
  Xi Li (1)
  Hang Su (5)
  Wanshou Qiu (1)
  
  1. Breast Cancer Center, The Third Affiliated Hospital of Sun Yat-sen University, 600 Tianhe Road, Guangzhou, Guangdong, 510630, China
  2. Department of Gland Surgery, Guangzhou Panyu Central Hospital, 8 Fuyudong Road, Qiaonan Street, Guangzhou, Guangdong, 511400, China
  3. Department of Breast Surgery, Guangzhou Red Cross Hospital, 396 Tongfuzhong Road, Guangzhou, Guangdong, 510220, China
  4. Department of General Surgery, Changsha Central Hospital, 161 Shaoshannan Road, Changsha, Hunan, 410004, China
  5. Department of Radiation Oncology, The University of Texas Health Science Center at San Antonio, 8403 Floyd Curl Drive, San Antonio, TX, 78229, USA
  
• 刊物主题：Cell Biology; Developmental Biology; Stem Cells; Cell Culture; Animal Genetics and Genomics;
• 出版者：Springer US
• ISSN：1543-706X

文摘

Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer with limited effective treatment options. New therapeutic approaches are urgently needed to improve the prognosis of TNBC. Here we demonstrated that a redox modulator, selenocystine (SeC), significantly inhibits TNBC cell proliferation in a dose- and time-dependent manner. Through cell apoptosis assays and cell cycle distribution analyses, we have shown that the in vitro inhibitory effect of SeC on TNBC cells can be attributed to the induction of apoptosis and the S-phase arrest in a dose-dependent manner. Therefore, this finding implies that SeC potentially is a novel therapeutic agent for TNBC. Keywords Selenocystine Apoptosis S-phase arrest Triple-negative breast cancer Proliferation